[The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tyrosine kinase inhibitors (TKIs) revolutionized non-small cell lung cancer (NSCLC) treatment for EGFR mutations.
• Classic EGFR mutations (exon 19 deletion, exon 21 L858R) respond well to first- to third-generation TKIs.
• EGFR exon 20 insertions represent a significant subset of EGFR mutations in NSCLC, often conferring drug resistance.

Purpose of the Study:

• To review the pathogenesis and molecular variants of EGFR exon 20 insertion mutations in NSCLC.
• To summarize current management strategies for EGFR exon 20 insertion mutant NSCLC.
• To highlight treatment challenges and future directions for this specific mutation.

Main Methods:

• Literature review of published studies on EGFR exon 20 insertion mutations in NSCLC.
• Analysis of pathogenesis, molecular characteristics, and clinical outcomes.
• Synthesis of current treatment approaches and identification of research gaps.

Main Results:

• EGFR exon 20 insertion mutations are associated with poor prognosis and intrinsic resistance to approved EGFR-TKIs.
• Most insertion variants exhibit de novo resistance to first- to third-generation EGFR-TKIs.
• There is a notable lack of comprehensive research and established clinical guidelines for managing this mutation.

Conclusions:

• EGFR exon 20 insertion mutations present unique therapeutic challenges in NSCLC due to drug resistance.
• Further research is crucial for developing effective targeted therapies and clinical guidelines for these patients.
• Understanding the specific amino acid sequence variants is key to overcoming treatment resistance.